<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Over 50% of patients with <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) will progress and/or develop <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Biomarkers capable of predicting progression, risk stratification and therapeutic benefit are needed </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> stem cells are thought to be responsible for <z:e sem="disease" ids="C0598935" disease_type="Neoplastic Process" abbrv="">tumor initiation</z:e>, dissemination and treatment failure </plain></SENT>
<SENT sid="3" pm="."><plain>Therefore, we hypothesized that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> stem cell markers (CRCSC) can identify a group of patients whom are at increased risk for recurrence or progression of disease </plain></SENT>
<SENT sid="4" pm="."><plain>If proven correct, these CRCSC biomarkers may herald a paradigm shift in the treatment of this deadly disease </plain></SENT>
<SENT sid="5" pm="."><plain>This manuscript reviews current <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> evidence based screening modalities, patient stratification, and summarizes the current state of biomarkers and discusses the novel concept of putative CRCSC's as prognostic biomarkers </plain></SENT>
</text></document>